These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 21504774)

  • 1. Immunogenicity and safety of AS03-adjuvanted H1N1 pandemic vaccines in children and adolescents.
    Garcia-Sicilia J; Gillard P; Carmona A; Tejedor JC; Aristegui J; Merino JM; Behre U; Caplanusi A; Vaman T; Dieussaert I
    Vaccine; 2011 Jun; 29(26):4353-61. PubMed ID: 21504774
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized, multicenter trial of a single dose of AS03-adjuvanted or unadjuvanted H1N1 2009 pandemic influenza vaccine in children 6 months to <9 years of age: safety and immunogenicity.
    Langley JM; Reich D; Aggarwal N; Connor D; Lebel MH; Gupta A; Garfield H; Li P; Madan A; Vaughn DW
    Pediatr Infect Dis J; 2012 Aug; 31(8):848-58. PubMed ID: 22801094
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term immunogenicity of an AS03-adjuvanted influenza A(H1N1)pdm09 vaccine in young and elderly adults: an observer-blind, randomized trial.
    Yang WH; Dionne M; Kyle M; Aggarwal N; Li P; Madariaga M; Godeaux O; Vaughn DW
    Vaccine; 2013 Sep; 31(40):4389-97. PubMed ID: 23856331
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity and safety of AS03-adjuvanted 2009 influenza A H1N1 vaccine in children 6-35 months.
    Carmona A; Omeñaca F; Tejedor JC; Merino JM; Vaman T; Dieussaert I; Gillard P; Arístegui J
    Vaccine; 2010 Aug; 28(36):5837-44. PubMed ID: 20600478
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and persistence of the humoral and cellular immune responses induced by 2 doses of an AS03-adjuvanted A(H1N1)pdm09 pandemic influenza vaccine administered to infants, children and adolescents: Two open, uncontrolled studies.
    Garcia-Sicilia J; Arístegui J; Omeñaca F; Carmona A; Tejedor JC; Merino JM; García-Corbeira P; Walravens K; Bambure V; Moris P; Caplanusi A; Gillard P; Dieussaert I
    Hum Vaccin Immunother; 2015; 11(10):2359-69. PubMed ID: 26176592
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An observer-blind, randomized, multi-center trial assessing long-term safety and immunogenicity of AS03-adjuvanted or unadjuvanted H1N1/2009 influenza vaccines in children 10-17 years of age.
    Poder A; Simurka P; Li P; Roy-Ghanta S; Vaughn D
    Vaccine; 2014 Feb; 32(9):1121-9. PubMed ID: 24252703
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An indirect comparison meta-analysis of AS03 and MF59 adjuvants in pandemic influenza A(H1N1)pdm09 vaccines.
    Hauser MI; Muscatello DJ; Soh ACY; Dwyer DE; Turner RM
    Vaccine; 2019 Jul; 37(31):4246-4255. PubMed ID: 31253447
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity and safety of an AS03-adjuvanted H5N1 pandemic influenza vaccine in Korean adults: a phase IV, randomized, open-label, controlled study.
    Izurieta P; Kim WJ; Wie SH; Lee J; Lee JS; Dramé M; Vaughn DW; Schuind A
    Vaccine; 2015 Jun; 33(24):2800-7. PubMed ID: 25910919
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-Term Persistence of Cell-Mediated and Humoral Responses to A(H1N1)pdm09 Influenza Virus Vaccines and the Role of the AS03 Adjuvant System in Adults during Two Randomized Controlled Trials.
    van der Most RG; Clément F; Willekens J; Dewé W; Walravens K; Vaughn DW; Leroux-Roels G
    Clin Vaccine Immunol; 2017 Jun; 24(6):. PubMed ID: 28446441
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and immunogenicity of an MF59-adjuvanted A/H1N1 pandemic influenza vaccine in children from three to seventeen years of age.
    Knuf M; Leroux-Roels G; Rümke HC; Abarca K; Rivera L; Lattanzi M; Pedotti P; Arora A; Kieninger-Baum D; Della Cioppa G
    Vaccine; 2015 Jan; 33(1):174-81. PubMed ID: 25444803
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Open-label, randomised, parallel-group, multicentre study to evaluate the safety, tolerability and immunogenicity of an AS03(B)/oil-in-water emulsion-adjuvanted (AS03(B)) split-virion versus non-adjuvanted whole-virion H1N1 influenza vaccine in UK children 6 months to 12 years of age.
    Waddington C; Andrews N; Hoschler K; Walker W; Oeser C; Reiner A; John T; Wilkins S; Casey M; Eccleston P; Allen R; Okike I; Ladhani S; Sheasby E; Waight P; Collinson A; Heath P; Finn A; Faust S; Snape M; Miller E; Pollard A
    Health Technol Assess; 2010 Oct; 14(46):1-130. PubMed ID: 20923610
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and long-term humoral immune response in adults after vaccination with an H1N1 2009 pandemic influenza vaccine with or without AS03 adjuvant.
    Ferguson M; Risi G; Davis M; Sheldon E; Baron M; Li P; Madariaga M; Fries L; Godeaux O; Vaughn D
    J Infect Dis; 2012 Mar; 205(5):733-44. PubMed ID: 22315336
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: open label, randomised, parallel group, multicentre study.
    Waddington CS; Walker WT; Oeser C; Reiner A; John T; Wilkins S; Casey M; Eccleston PE; Allen RJ; Okike I; Ladhani S; Sheasby E; Hoschler K; Andrews N; Waight P; Collinson AC; Heath PT; Finn A; Faust SN; Snape MD; Miller E; Pollard AJ
    BMJ; 2010 May; 340():c2649. PubMed ID: 20508026
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extended antigen sparing potential of AS03-adjuvanted pandemic H1N1 vaccines in children, and immunological equivalence of two formulations of AS03-adjuvanted H1N1 vaccines: results from two randomised trials.
    Launay O; Duval X; Fitoussi S; Jilg W; Kerdpanich A; Montellano M; Schwarz TF; Watanveerade V; Wenzel JJ; Zalcman G; Bambure V; Li P; Caplanusi A; Madan A; Gillard P; Vaughn DW
    BMC Infect Dis; 2013 Sep; 13():435. PubMed ID: 24041010
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Narcolepsy, 2009 A(H1N1) pandemic influenza, and pandemic influenza vaccinations: what is known and unknown about the neurological disorder, the role for autoimmunity, and vaccine adjuvants.
    Ahmed SS; Schur PH; MacDonald NE; Steinman L
    J Autoimmun; 2014 May; 50():1-11. PubMed ID: 24559657
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and immunogenicity of an AS03-adjuvanted A(H1N1)pmd09 vaccine administered simultaneously or sequentially with a seasonal trivalent vaccine in adults 61 years or older: data from two multicentre randomised trials.
    Peeters M; Regner S; Vaman T; Devaster JM; Rombo L
    Vaccine; 2012 Oct; 30(45):6483-91. PubMed ID: 22885014
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II, randomized, open, controlled study of AS03-adjuvanted H5N1 pre-pandemic influenza vaccine in children aged 3 to 9 years: follow-up of safety and immunogenicity persistence at 24 months post-vaccination.
    Díez-Domingo J; Baldó JM; Planelles-Catarino MV; Garcés-Sánchez M; Ubeda I; Jubert-Rosich A; Marès J; Garcia-Corbeira P; Moris P; Teko M; Vanden Abeele C; Gillard P
    Influenza Other Respir Viruses; 2015 Mar; 9(2):68-77. PubMed ID: 25652873
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Flexibility of interval between vaccinations with AS03A-adjuvanted influenza A (H1N1) 2009 vaccine in adults aged 18-60 and >60 years: a randomized trial.
    Duval X; Caplanusi A; Laurichesse H; Deplanque D; Loulergue P; Vaman T; Launay O; Gillard P
    BMC Infect Dis; 2012 Jul; 12():162. PubMed ID: 22824474
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity and safety of a two-dose schedule of whole-virion and AS03A-adjuvanted 2009 influenza A (H1N1) vaccines: a randomised, multicentre, age-stratified, head-to-head trial.
    Nicholson KG; Abrams KR; Batham S; Clark TW; Hoschler K; Lim WS; Medina MJ; Nguyen-Van-Tam JS; Read RC; Warren FC; Zambon M
    Lancet Infect Dis; 2011 Feb; 11(2):91-101. PubMed ID: 21168369
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A clinical phase I study of an EB66 cell-derived H5N1 pandemic vaccine adjuvanted with AS03.
    Naruse T; Fukuda T; Tanabe T; Ichikawa M; Oda Y; Tochihara S; Kimachi K; Kino Y; Ueda K
    Vaccine; 2015 Nov; 33(45):6078-84. PubMed ID: 26409141
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.